<DOC>
	<DOCNO>NCT02506231</DOCNO>
	<brief_summary>The purpose study assess impact folinic acid ( FA ) -rescue follow methotrexate ( MTX ) graft-versus-host disease ( GVHD ) prophylaxis regimen related toxicity transplantation outcomes allogeneic hematopoietic cell transplantation ( alloHCT ) double blind randomize controlled trial .</brief_summary>
	<brief_title>The Effect Folinic Acid Rescue Following MTX GVHD Prophylaxis Regimen Related Toxicity Transplantation Outcome</brief_title>
	<detailed_description>A regimen consist combination calcineurin inhibitor ( CNI ) short course methotrexate ( MTX ) widely use regimen prevention GVHD allogeneic hematopoietic cell transplantation ( alloHCT ) . While CNI give adjust dose , base blood level , MTX give fix 3 4 dos ( 15 mg/m2 day +1 , 10 mg/m2 day +3 , +6 +/- day +11 ) . However , use may associate considerable toxicity , include delay engraftment , hepatotoxicity , nephrotoxicity particularly oral mucositis ( OM ) . The basis OM integrate : conditioning regimen MTX prophylaxis acute GVHD . OM show associate increased mortality morbidity ( principally infection ) , significant pain , dysgeusia , difficulty speaking , difficulty receive nutrition , hydration oral medication , prolonged hospitalization increase cost care . Reducing even omit dos MTX due regimen related toxicity ( mucositis , hepatic renal toxicity ) common . However , dose reduction MTX may associate increase risk acute GVHD early death . Several non-randomized study show folinic acid ( FA , leucovorin ) administration may reduce MTX toxicity . Nevertheless , efficacy safety administration remain controversial . Despite limited uncontrolled data , European Group Blood Marrow Transplantation ( EBMT ) European LeukemiaNet work group recently recommend use FA-rescue propose uniform policy FA-rescue 24h MTX dose : 15mg every 8h MTX administration day 1 , every 6h day 3 , 6 11 . Yet , accord several survey ( include EBMT-ELN ) half bone marrow transplantation ( BMT ) center use give post MTX FA-rescue . The aim study assess impact FA-rescue follow MTX GVHD prophylaxis regimen related toxicity transplantation outcomes alloHCT double blind randomize control trial .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Acute leukemia complete remission ( CR ) myelodysplastic syndrome ; First transplantation ; Peripheral blood graft ; Matched sibling unrelated donor one antigen allelic mismatch sibling unrelated donor ( 10/10 9/10 human leukocyte antigen match ) ; Myeloablative reduce intensity preparative regimen ; Posttransplant GVHD prophylaxis consist calcineurin inhibitor ( CSA tacrolimus ) methotrexate ; Glutamate Pyruvate Transaminase ( GPT ) &lt; 3 time upper normal limit ( UNL ) creatinine â‰¤ 1.4 mg % ; Written inform consent ; True nonmyeloablative preparative regimen ( TBI 200 +/ fludarabine ) ; Acute leukemia remission ; GPT &gt; 3 time upper normal limit creatinine &gt; 1.4 mg % ; Bone marrow , haploidentical cord blood graft ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Allogeneic hematopoietic cell transplantation</keyword>
	<keyword>GVHD prophylaxis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Folinic acid</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Mucositis</keyword>
</DOC>